Novo Nordisk Stock Plummets After Heart Drug Trial

Novo Nordisk’s stock price fell sharply following disappointing results from a clinical trial of a new heart medication. The trial failed to show the drug’s effectiveness in treating heart conditions. This news raises concerns about the company’s future development and potential impact on its overall strategy.

Summarized from the sources above. Read the originals for the full story.